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Progression of radiological joint damage is usually based
on the simultaneous assessment of a series of films from an
individual patient (‘‘paired’’, with or without known
sequence). In this setting the degree of progression that can
be reliably detected above the measurement error is best
determined by the smallest detectable change, and
overestimated by the traditionally calculated smallest
detectable difference. This knowledge is important for
calculation of the proportion of patients showing
radiographic progression in clinical trials.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
See end of article for
authors’ affiliations
. . . . . . . . . . . . . . . . . . . . . . .
Correspondence to:
Professor D van der
Heijde, Department of
Internal Medicine, Division
of Rheumatology,
University Hospital
Maastricht, PO Box 5800,
6202 AZ Maastricht, The
Netherlands;
dhe@sint.azm.nl
Accepted 16 July 2004
Published Online First
29 July 2004
. . . . . . . . . . . . . . . . . . . . . . .
I
n therapeutic trials the main interest is usually
the analysis based on the mean or median
change at a group level of the outcome
measure(s) over time. The percentage of patients
responding to a particular intervention is, how-
ever, included increasingly in trial analyses
because this can add valuable information.1
Presenting the percentage of (non) responders
helps the practising rheumatologist to individua-
lise group data found in trials, the ultimate goal
of evidence based medicine. It further enables
the practitioner to calculate the so-called number
needed to treat (NNT).2
For the interpretation of radiological progres-
sion of joint damage due to rheumatoid arthritis
(RA) in the hands and feet it can be also very
useful to present the number patients responding
in addition to the means and medians.3
Particularly, because radiographic data show a
highly skewed distribution pattern, the majority of
patients show only mild or no progression in the
observation period, and only a subset of patients
show substantial progression. Note that for radi-
ological joint damage due to RA, ‘‘response’’ can
be translated as no progression of damage (and
theoretically, also improvement or repair).
To determine the percentage of patients who
showed a relevant change over time continuous
data have to be dichotomised, and thus a valid
and clinically relevant cut off level should be
chosen (called the minimal clinically important
difference). It seems logical that such a cut off
value should at least be greater than the
measurement error of the instrument used to
quantify the response. As a starting point the
smallest detectable difference (SDD) has there-
fore been suggested as the cut off level.3–5 The
SDD expresses the smallest difference between
two independently obtained measures that can be
interpreted as ‘‘real’’—that is, a difference
greater than the measurement error.
Radiological joint damage due to RA is usually
assessed with the films of one particular patient
side by side—that is, simultaneously. The pur-
pose of the simultaneous reading of the films is
that the raters can compensate for variation in
positioning of the hands and feet and in film
quality, minimising the measurement error.6 7
But when films are read side by side, the
measures are not obtained independently and
therefore the SDD is not the appropriate way to
define a cut off level.
This paper aims at presenting the way in
which the smallest change in scores that can be
deemed as a ‘‘real’’ change can be assessed
correctly, from here on called the smallest
detectable change (SDC) for the setting in which
films are read simultaneously. In subsequent
paragraphs, we will first explain further why the
regular SDD should not be used. Then, we will
describe two methods of estimating the mea-
surement error of change and accompanying
SDC. Finally, we will give an example of both
calculations based on the reliability data of 10
random subjects of the COBRA trial8 and
demonstrate that if films are scored simulta-
neously, the SDD results in a cut off level which
is too high to detect change in an individual
patient.
READING RADIOGRAPHS AS SINGLE
FILMS COMPARED WITH READING AS
PAIRS
Whether the SDD or the SDC should be used to
determine if a patient’s score has changed more
than the measurement error depends on whether
the change is based on two independently obtained
scores or not.
Radiographs can be presented to a rater
completely at random—that is, a single film at
a time, or they can be grouped for each patient so
that all films of one particular patient are read
simultaneously, with or without data on the
sequence of the films. As mentioned briefly in
the introduction, reading all films of one patient
simultaneously has the major advantage that the
rater will be able to correct for variation in
positioning of the hands and feet or variation of
the film quality. When films are grouped for each
patient, a rater compares all the films of one
Abbreviations: ANOVA, analysis of variance; SDC,
smallest detectable change; SDD, smallest detectable
difference
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patient and judges whether a change in joint damage has
occurred. Paired (without information on the chronology of
the films) or sequenced (with information on the chronology
of the films) reading thereby aims at reducing the measure-
ment error of the object of interest in trials: the change
in joint damage. However, the measurement errors of
the scores are thereby correlated and are no longer
independent. Furthermore, the change-score (the score
obtained by subtracting the status-score at time 1 from
the status-score at time 2) can actually be interpreted as a
single score. Because one actually tests the hypothesis
whether the difference between two independent status-scores
differs from 01 5 9 10 when determining a regular SDD, it
is inappropriate to use an SDD based on dependent status-
scores.
CHANGE IN AN INDIVIDUAL PATIENT COMPARED
WITH CHANGE BETWEEN PATIENTS
To determine if the scores of a patient changed over time in
the case of dependent scores, the hypothesis to be tested
should be whether the change-score in an individual patient
differs from 0. In the past, researchers have calculated SDDs
based on the change-score. However, with SDDs based on
change-scores, one actually tests the hypothesis whether the
difference between two independent change-scores differs
from 0. So the SDD based on change-scores is the correct
measure if we want to test whether the change-score from
one patient is different from the change-score of another
patient. However, when we want to assess if an individual
patient shows progression, this is not appropriate and an
alternative, the SDC, should be used.
Note that with independent scores we do not refer to the
condition that scores of one person are independent
statistically. Scores of one patient are always paired observa-
tions and thereby statistically dependent. With independent
scores we refer to the fact that the measurement error of the
scores of the films from time 2 is not related to the
measurement error of the scores of the films from time 1.
When scoring films of times 1 and 2 simultaneously this is
not true.
APPROPRIATE METHODS TO ASSESS THE SDC FOR
SIMULTANEOUS READING OF FILMS
In the field of radiological joint damage, it is customary to
assess the measurement error of the scoring methods by
rescoring the radiographs by the same rater (intrarater
reliability) or by a different rater (interrater reliability). The
option of obtaining a second radiograph is never applied on a
large scale in trials because this would require additional
exposure of the patients to radiation. Because the same
radiographs are re-examined, differences between the two
observations on each individual subject are caused by
measurement error.
Here we shall describe two correct methods of estimating
the measurement error of the change-score of two simulta-
neously scored films and the accompanying SDC. The first
method quantifies measurement error by the standard error
of measurement of the change-score (SEMCHANGE-SCORE)
derived from a two way analysis of variance (ANOVA).
The second method estimates the measurement error by
calculating the standard deviation of the difference between
change-scores of two reading sessions (SDD(CHANGE-SCORES)).
The latter resembles the estimation of the measurement
error as described by Bland and Altman,4 9 in which the
standard deviation of the difference between status scores of
two reading sessions (SDD(STATUS-SCORES)) estimates the
measurement error. This second method is only applicable
for two raters or one repetition; the first method, using
an ANOVA analysis, can be applied also if measurements
of three or more raters or two or more repetitions are
available.
Measurement error estimated with the
SEMCHANGE-SCORE
For this method one runs a two way ANOVA to estimate
measurement error expressed by the SEMCHANGE-SCORE, with
the change-scores of repeated measurements or the change-
scores of two or more raters. The two way ANOVA will result
in mean squares for the different sources of variation in the
change-scores. These are the between-patient variation
(variance caused by the variation in change between the
patients) and the within-patient variance. The within-patient
variance is composed of the variance caused by the systemic
variation between the first and the second reading session or
the first and the second rater (between-measurement
variation) and the random variation in change-scores (the
residual error). The SEM is calculated by taking the square
root of the error variance. The error variance can constitute
the total within-patient variance (including the between-
measurement variance) or the residual variance only. If one
does not want to generalise to other raters not included in
the reliability study, the between-measurement variance
should not be included in the error variance. In this paper
we will base the SEMCHANGE-SCORE on residual error, only,
to be able to compare directly the SDC calculated with an
SEMCHANGE-SCORE with the SDC calculated with the
SDD(CHANGE-SCORES).
Because an SEM is a variable that expresses the amount of
measurement error in the original metric unit of the
measurement it can be used to calculate an interval of error
around scores, assuming that the measurement error is
distributed normally. At the 95% confidence level, the
interval around a change-score is calculated according to
the formula:
change-score ¡ (1.966SEMCHANGE-SCORE/!k)
where k represents the number of readings or raters used for
the actual analyses of a trial. For a trial in which the results
are based on the mean scores of k raters/readings, the
measurement error diminishes by a factor !k.
If a calculated 95% interval around a change-score contains
the value 0, the null hypothesis that the change-score is 0
cannot be rejected. So, values of the change-score lying in
this interval other than 0 might be induced by error alone. On
the other hand, if the interval does not include 0 we reject the
null hypothesis and conclude that the change-score really
differs from 0 and state that there is a ‘‘real’’ change in joint
damage.
From the formula of the 95% interval around the change-
score we can see that a change-score larger than
¡1.966SEMCHANGE-SCORE/!k can be regarded as larger than
the measurement error. This formula is thus the formula
used to calculate the SDC based on change-scores obtained
with simultaneous reading of films.
Please note that the absolute change-score (that is,
disregarding the sign) needs only to be half the size of the
full interval around the change-score. In other words: in the
case of two readings, the first can be either larger or smaller
than the second purely by measurement error, and the full
range of possible changes (with positive and negative sign) is
described by the interval in the formula. However, once we
find that the first reading is larger than the second we will
reject the null hypothesis once the change falls outside
the range of the interval, in this case on the positive side.
This will occur when the change is half the size of the full
interval.
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Measurement error estimated with the SD of the
differences between change-scores of two reading
sessions (SDD (CHANGE-SCORES))
If repeated measurements or scores of two raters are used
to assess the SDC, the measurement error can also be
estimated with the standard deviation of the differ-
ences between change-scores of two reading sessions
(SDD(CHANGE-SCORES)). For this method one firstly calculates
the differences between the change-scores obtained in the
repeated reading session. Secondly, the SD of these differ-
ences is calculated. This SDD(CHANGE-SCORES) reflects the
measurement error of the difference between two change-
scores—that is, the measurement error when discriminating
between two change-scores. However, for evaluating a
clinical trial one is interested in whether a change-score in
an individual patient really can be distinguished from 0 (in
other words, if progression of damage is seen in this patient)
and not whether two change-scores differ from each other
(in other words, if the progression in one patient is
significantly different from the progression in another
patient). The measurement error of a single change-score is
obtained by dividing the SDD(CHANGE-SCORES) by !2.10 The
error interval around a change-score, at the 95% confidence
level, is further calculated by:
change-score ¡ (1.966SDD(CHANGE-SCORES))/(!26!k)
and the SDC by:
¡ 1.966SDD(CHANGE-SCORES)/(!26!k)
in which k again represents the number of readings over
which one wants to average the analyses of the trial. These
formulae show that:
SDD(CHANGE-SCORES)/(!26!k) = SEMCHANGE-SCORE/!k
if the data of one repetition or two raters is used.11
EXAMPLE OF THE TWO METHODS TO ASSESS THE
SDC FOR SCORES BASED ON SIMULTANEOUS
READING OF FILMS
In this section we will show both calculations for the
reliability data of 10 subjects from the COBRA trial.8 These
10 subjects were randomly selected from the subgroup of
patients showing progression of ,25 Sharp/van der Heijde
(90th centile) to ensure homoscedasticity. As we know that
radiological data are often highly skewed and because it is
known that measurement error tends to be larger in patients
with more baseline damage and radiological progression,4 the
assumption of homoscedasticity can be violated.
Table 1 shows the status and change-scores of two differ-
ent raters of the 10 subjects, and table 2 shows the two way
ANOVA for the change-scores. The SDD(CHANGE-SCORES) in
this example is 2.06 and the SEMCHANGE-SCORE, calculated by
extracting the root of the residual mean square (!2.12), is
1.46. Putting these figures into the formulae presented in the
section above results in both cases in an SDC of 2.85 scoring
units, if not using average scores (k = 1).
OVERESTIMATION OF THE MEASUREMENT ERROR
BY THE SDD
To complete this report, we will show that if one uses the
regular SDD—for example determined with the baseline
status scores of the two raters—to determine whether a
patient’s scores have really changed, this will result in an
overestimation of the measurement error. The SDD according
to Bland and Altman4 9 is estimated by calculating a 95%
interval around the difference between two single status
scores with the formula:
Table 1 Scores of two different raters of 10 patients
Subject
Baseline score Difference
status-scores
between raters
Change score Difference
change-scores
between raters1st Rater 2nd Rater 1st Rater 2nd Rater
1 12 15 3 2 3 1
2 0 0 0 0 0 0
3 23 20 23 9 10 1
4 5 2 23 4 1 23
5 7 11 4 11 10 21
6 3 0 23 1 0 21
7 0 0 0 0 0 0
8 1 1 0 5 8 3
9 9 6 23 17 13 24
10 19 25 6 10 11 1
Mean 0.1 20.3
SD 3.28 2.06
Table 2 Two way analysis of variance for the change-
score data of table 1
Source of variation
Degrees of
freedom Sum of squares Mean square
Between-patient* 9 520.25 57.81
Within-patient 10 19.50 1.95
Between-
measurement`
1 0.45 0.45
Residual1 9 19.05 2.12
Total 19 539.75
* Variance in scores due to differences between patients; variance in
scores due to differences within a patient; `variance in scores due to the
differences between the raters; 1variance in scores due to unknown
sources.
Table 3 Two way analysis of variance for the baseline
status-score data of table 1
Source of variation
Degrees of
freedom Sum of squares Mean square
Between-patient* 9 1298.45 144.27
Within- patient 10 48.5 4.85
Between-
measurement`
1 0.05 0.05
Residual1 9 48.45 5.38
Total 19 1346.95
Joint damage progression in paired films 181
www.annrheumdis.com
¡1.966!26(SEMSTATUS-SCORE/!k
or by
¡1.966SDD(STATUS-SCORES)/!k
Calculating the SDD with the SDD(STATUS-SCORES) (see
table 1; ¡1.9663.28/!k) or with the SEMSTATUS-SCORE (see
table 3; ¡1.966!26!5.38/!k) results in an SDD of 6.4 units if
not using average scores (k = 1). So, the measurement error
of detecting a change within patients is clearly smaller than
the measurement error of detecting a difference between two
single baseline scores, as expected.
Conclusions
In summary, progression of radiological joint damage is
usually based on simultaneous assessment of a series of films
from an individual patient (‘‘paired’’, with or without known
sequence). In this setting, the amount of progression that is
reliably detectable above the measurement error is best
determined by the smallest detectable change, and over-
estimated by the traditionally calculated smallest detectable
difference. This is important knowledge for the calculation of
the proportion of the patients showing radiographic progres-
sion in clinical trials.
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